Search Results

Press Releases

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

December 18, 2024

·

4 min read

Mergers & acquisitions

Roche Nears Completion of Poseida Acquisition Worth Up to $1.5B

In a deal expected to close in Q1 2025, Roche will gain access to Poseida’s off-the-shelf CAR T candidates.

January 8, 2025

·

3 min read

·

Tristan Manalac

Immunology & inflammation

Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M

The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to develop and commercialize therapies for an undisclosed autoimmune disease.

December 3, 2024

·

1 min read

·

Heather McKenzie

Antibody drug conjugate

Roche Kicks Off 2025 Committing a Potential $1B for Another ADC From China

Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal with Innovent for $1 billion in biobucks.

January 2, 2025

·

2 min read

·

Annalee Armstrong

Policy

Roche receives FDA clearance on its digital pathology solution for diagnostic use

Roche announced that its whole-slide imaging system, the Roche Digital Pathology Dx, has received 510 clearance from the United States Food and Drug Administration.

June 18, 2024

·

3 min read

Weight loss

Roche’s Obesity Pill Candidate Hit With Safety Concerns Despite Strong Efficacy Data

When doses were increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal distension.

September 12, 2024

·

2 min read

·

Tristan Manalac

Business

Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing

Roche announced that Hitachi High-Tech and Roche have extended their partnership, committing to at least 10 years of additional collaboration.

May 27, 2024

·

5 min read

Deals

Roche Inks Potential $1.8B Deal With Flare to Target Transcription Factors in Cancer

With $70 million upfront and more than $1.8 billion on the line, Roche will gain access to Flare’s drug discovery engine to bolster its oncology pipeline.

November 12, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Roche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERA

November 25, 2024

·

6 min read

Press Releases

Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease

October 31, 2024

·

8 min read